|
124 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
11 Trials |
|
2428 News |
|
| «12...89101112131415161718...4950» |
- |||| Isentress (raltegravir) / Merck (MSD)
Trial completion, Phase classification: Effect of Raltegravir on Endothelial Function in HIV-Infected Patients (clinicaltrials.gov) - Jun 10, 2015
P4, N=56, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed | Phase classification: PN/A --> P4
- Isentress (raltegravir) / Merck (MSD)
Enrollment change, Trial termination: Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery (clinicaltrials.gov) - Jun 9, 2015
P3, N=20, Terminated, Sponsor: Pedro Cahn
Active, not recruiting --> Completed | Phase classification: PN/A --> P4 N=60 --> 20 | Active, not recruiting --> Terminated; recruitment lower than estimated
- Enrollment closed, Trial primary completion date: Veterans Living With HIV/AIDS: A Pilot Study Examining Risk Factors Associated With Self-Directed Violence (clinicaltrials.gov) - Jun 9, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: VA Eastern Colorado Health Care System
N=60 --> 20 | Active, not recruiting --> Terminated; recruitment lower than estimated Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Sep 2015
- Trial completion, Enrollment change: Tissue Drug Levels of HIV Medications (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=22, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Sep 2015 Active, not recruiting --> Completed | N=40 --> 22
- ||| Trial completion: Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study) (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=230, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed | N=40 --> 22 Active, not recruiting --> Completed
- ||||||| Trial completion: Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO) (clinicaltrials.gov) - Jun 3, 2015
P3, N=2073, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion: The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk (clinicaltrials.gov) - Jun 2, 2015
P=N/A, N=270, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment change, HEOR: HIV Educational Programs for Villagers of Funan County or Yingzhou District, Anhui Province, China (clinicaltrials.gov) - Jun 1, 2015
P1, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed N=3830 --> 0
- GSK2838232 / GSK
Enrollment open: A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects (clinicaltrials.gov) - Jun 1, 2015
P1, N=40, Recruiting, Sponsor: GlaxoSmithKline
N=3830 --> 0 Suspended --> Recruiting
- GSK2838232 / GSK
Enrollment closed: A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects (clinicaltrials.gov) - Jun 1, 2015
P1, N=20, Active, not recruiting, Sponsor: GlaxoSmithKline
Suspended --> Recruiting Suspended --> Active, not recruiting
- || Selzentry (maraviroc) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Trial completion, Trial primary completion date: Effects of Intensive cART During Acute/Early HIV Infection (clinicaltrials.gov) - Jun 1, 2015
P2/3, N=32, Completed, Sponsor: University of Toronto
Suspended --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Sep 2014
- ||||||| Tybost (cobicistat) / Gilead, Evotaz (atazanavir/cobicistat) / Gilead, BMS
Trial completion: Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Jun 1, 2015
P3, N=698, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Sep 2014 Active, not recruiting --> Completed
- ||| trimethoprim/sulfamethoxazole / Generic mfg.
Trial completion: Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART na (clinicaltrials.gov) - May 29, 2015
P=N/A, N=500, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults (clinicaltrials.gov) - May 28, 2015
P3, N=100, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV (clinicaltrials.gov) - May 28, 2015
P=N/A, N=451, Completed, Sponsor: University of California, Los Angeles
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Enrollment closed: Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults (clinicaltrials.gov) - May 27, 2015
P2, N=360, Active, not recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- zoledronic acid / Generic mfg.
Enrollment closed: Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV) (clinicaltrials.gov) - May 27, 2015
P2, N=78, Active, not recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed, Enrollment change: Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand (clinicaltrials.gov) - May 27, 2015
P=N/A, N=2816, Active, not recruiting, Sponsor: Institut de Recherche pour le Developpement
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=2000 --> 2816
- ||||||| Vitekta (elvitegravir) / Japan Tobacco, Gilead
Trial completion: Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir (clinicaltrials.gov) - May 26, 2015
P3, N=724, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | N=2000 --> 2816 Active, not recruiting --> Completed
- Trial completion, Enrollment change: Effects of HIV and Hepatitis C Virus on the Brain (clinicaltrials.gov) - May 26, 2015
P=N/A, N=78, Completed, Sponsor: Mount Sinai School of Medicine
Active, not recruiting --> Completed Recruiting --> Completed | N=200 --> 78
- || lopinavir/ritonavir / Generic mfg.
Enrollment change, Trial primary completion date, Combination therapy: PROTEKT: Kaletra in Combination With Antiretroviral Agents (clinicaltrials.gov) - May 22, 2015
P=N/A, N=550, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed | N=200 --> 78 N=450 --> 550 | Trial primary completion date: Feb 2018 --> Jan 2016
- | Isentress (raltegravir) / Merck (MSD)
Enrollment closed: Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy (clinicaltrials.gov) - May 22, 2015
P3, N=1800, Active, not recruiting, Sponsor: Anna Griffiths, MRC
N=450 --> 550 | Trial primary completion date: Feb 2018 --> Jan 2016 Recruiting --> Active, not recruiting
- atorvastatin / Generic mfg.
Trial completion, IO biomarker: Atorvastatin for HAART Suboptimal Responders (clinicaltrials.gov) - May 21, 2015
P3, N=30, Completed, Sponsor: Makerere University
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Enrollment change: Raltegravir Activity In Lymphoid Tissues (clinicaltrials.gov) - May 19, 2015
P=N/A, N=0, Withdrawn, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting --> Completed N=10 --> 0
- Enrollment change: Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment (clinicaltrials.gov) - May 19, 2015
P3, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=10 --> 0 N=140 --> 0
- | Trial completion, Adherence: DASH: Durability of Adherence in Self-Management of HIV (clinicaltrials.gov) - May 19, 2015
P3, N=213, Completed, Sponsor: AIDS Clinical Trials Group
N=140 --> 0 Active, not recruiting --> Completed
- | efavirenz / Generic mfg., rifampicin / Generic mfg.
Trial completion, Trial primary completion date: A06-295: An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin (clinicaltrials.gov) - May 19, 2015
P4, N=30, Completed, Sponsor: Oswaldo Cruz Foundation
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2009 --> Dec 2012
- | stavudine / Generic mfg., ribavirin / Generic mfg., zidovudine / Generic mfg.
Trial completion: Effects of Ribavirin on Zidovudine or Stavudine (clinicaltrials.gov) - May 17, 2015
P=N/A, N=32, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial primary completion date: Dec 2009 --> Dec 2012 No longer recruiting --> Completed
- | amprenavir / Generic mfg., abacavir / Generic mfg.
Trial completion, Combination therapy: Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients (clinicaltrials.gov) - May 16, 2015
P=N/A, N=25, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed: OPG-2: Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis (clinicaltrials.gov) - May 13, 2015
P=N/A, N=120, Active, not recruiting, Sponsor: Emory University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion, Enrollment change, Trial primary completion date: Examination of B Cell Responses in Human Blood (clinicaltrials.gov) - May 13, 2015
P=N/A, N=50, Completed, Sponsor: Regenerative Medicine Network
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=40 --> 50 | Trial primary completion date: Dec 2010 --> Dec 2009
- Isentress (raltegravir) / Merck (MSD)
Phase classification: RALPIR: Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria (clinicaltrials.gov) - May 12, 2015
P=N/A, N=20, Completed, Sponsor: Metropolis Medical
Active, not recruiting --> Completed | N=40 --> 50 | Trial primary completion date: Dec 2010 --> Dec 2009 Phase classification: P4 --> P=N/A
- ||| darunavir/ritonavir / Generic mfg.
Enrollment closed: DUAL: Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject (clinicaltrials.gov) - May 12, 2015
P4, N=256, Active, not recruiting, Sponsor: Fundacion SEIMC-GESIDA
Phase classification: P4 --> P=N/A Recruiting --> Active, not recruiting
- Enrollment closed, HEOR: Medical Marijuana Use in HIV+ Patients Prospective Cohort Study (clinicaltrials.gov) - May 12, 2015
P=N/A, N=150, Active, not recruiting, Sponsor: Wayne State University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Trial completion, Head-to-Head: SALT: Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy (clinicaltrials.gov) - May 12, 2015
P4, N=286, Completed, Sponsor: Fundacion SEIMC-GESIDA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Isentress (raltegravir) / Merck (MSD)
Trial completion, Combination therapy: A Study to Assess the Efficacy of Raltegravir (Isentress (clinicaltrials.gov) - May 12, 2015
P=N/A, N=451, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- mupirocin / Generic mfg.
Trial primary completion date: Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons (clinicaltrials.gov) - May 8, 2015
P=N/A, N=550, Active, not recruiting, Sponsor: Uniformed Services University of the Health Sciences
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Dec 2015
- Enrollment change, Trial withdrawal: The Feasibility of Using a General Health Screen to Increase HIV Testing in Community Pharmacies (clinicaltrials.gov) - May 8, 2015
P=N/A, N=0, Withdrawn, Sponsor: North Bronx Healthcare Network
Trial primary completion date: Dec 2014 --> Dec 2015 N=1200 --> 0 | Not yet recruiting --> Withdrawn
- Enrollment change: ICONIC: Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility (clinicaltrials.gov) - May 8, 2015
P=N/A, N=10, Terminated, Sponsor: University of Florida
N=1200 --> 0 | Not yet recruiting --> Withdrawn N=100 --> 10
- Trial completion, Enrollment change: Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons (clinicaltrials.gov) - May 8, 2015
P=N/A, N=233, Completed, Sponsor: Uniformed Services University of the Health Sciences
N=100 --> 10 Active, not recruiting --> Completed | N=300 --> 233
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults (clinicaltrials.gov) - May 7, 2015
P3, N=170, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | N=300 --> 233 Trial primary completion date: Feb 2015 --> Aug 2015
- lopinavir/ritonavir / Generic mfg.
Trial completion, Enrollment change: AP6142: Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir) (clinicaltrials.gov) - May 7, 2015
P1, N=18, Completed, Sponsor: University of California, San Francisco
Trial primary completion date: Feb 2015 --> Aug 2015 Active, not recruiting --> Completed | N=24 --> 18
- | Vocabria (cabotegravir oral) / ViiV Healthcare
Enrollment closed: Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir (clinicaltrials.gov) - May 6, 2015
P3, N=36, Active, not recruiting, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed | N=24 --> 18 Recruiting --> Active, not recruiting
- Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Enrollment closed, Compliance: Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera (clinicaltrials.gov) - May 6, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Prema Menezes, PhD, PA-C
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial primary completion date: Eliciting Affect in Teens in a Virtual World (Project AVATAR) (clinicaltrials.gov) - May 5, 2015
P1/2, N=100, Recruiting, Sponsor: Rhode Island Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Aug 2015
- Trial primary completion date: Fish Oil for HIV-Related Inflamm-aging and Immune Senescence (clinicaltrials.gov) - May 5, 2015
P2, N=38, Recruiting, Sponsor: Rush University Medical Center
Trial primary completion date: Mar 2015 --> Aug 2015 Trial primary completion date: Feb 2015 --> Dec 2015
- Trial completion, Trial primary completion date: Smoking Cessation for HIV/AIDS Patients (clinicaltrials.gov) - May 5, 2015
P=N/A, N=706, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Feb 2015 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Apr 2015
- || Vivitrol (naltrexone extended-release injectable suspension) / Alkermes
Enrollment closed, Trial primary completion date: INSPIRE: Alcohol Pharmacotherapy for HIV+ Prisoners (clinicaltrials.gov) - May 1, 2015
P=N/A, N=125, Active, not recruiting, Sponsor: Yale University
Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Apr 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Aug 2016
- metformin / Generic mfg., pioglitazone / Generic mfg.
Enrollment closed: Metabolic Abnormalities in HIV-infected Persons (clinicaltrials.gov) - Apr 30, 2015
P4, N=70, Active, not recruiting, Sponsor: Tufts Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Aug 2016 Recruiting --> Active, not recruiting
- Enrollment closed: Treatment Advocacy Intervention for HIV-Positive African Americans (clinicaltrials.gov) - Apr 30, 2015
P2, N=200, Active, not recruiting, Sponsor: Children's Hospital Boston
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting